Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company located in Woburn, MA, focuses on pioneering tumor-directed oncolytic immunotherapies. On March 15, 2023, the management will present at the Barclays Global Healthcare Conference at 2:05 pm EDT in Miami, FL. They will also hold in-person investor meetings at the Jefferies Biotech on the Bay Summit. Replimune's innovative RPx platform utilizes a potent HSV-1 backbone designed to enhance immunogenic cell death and trigger systemic anti-tumor responses. The dual mechanism of action allows for synergistic effects with various cancer treatment modalities, showcasing its versatile and attractive safety profile.
- None.
- None.
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
Barclays Global Healthcare Conference
Date: Wednesday, March 15, 2023
Fireside Chat Time: 2:05 pm EDT
Location: The Loews Miami Beach Hotel, Miami, FL
Jefferies Biotech on the Bay Summit
Location: 1 Hotel South Beach, Miami, FL
In-person 1x1 investor meetings only
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com
FAQ
When is Replimune presenting at the Barclays Global Healthcare Conference?
Where is the Barclays Global Healthcare Conference being held?
What is the purpose of the Jefferies Biotech on the Bay Summit for Replimune?
What is Replimune's primary focus?
What is the RPx platform developed by Replimune?
